Abstract
We previously demonstrated that increased dietary salt markedly decreases plasma quinidine concentrations shortly after p.o. dosing, without an effect on the drug’s terminal elimination half-life or concentrations after i.v. administration. These findings suggest an effect of dietary salt on intestinal metabolism or transport of the drug. Because one effect of salt loading is sympathetic inhibition, we examined the effect of β-adrenoceptor blockade on salt-related changes in quinidine disposition. Furthermore, we examined whether the action of salt is local or systemic by determining the effect of salt loading by the i.v. route. To assess the effect of β-blockade, quinidine disposition was studied in eight normal volunteers after a single p.o. dose of quinidine; data were obtained after 1 week on a high-salt diet (400 mEq/day) and 1 week on a low-salt diet (10 mEq/day) during chronic nadolol and compared with those previously obtained in the same subjects without the β-blocker. β-Blockade had no effect on oral clearance during the high-salt diet [0.28 ± 0.1 (quinidine + nadolol) versus 0.30 ± 0.2 liters/h/kg (quinidine alone)] but increased clearance on the low-salt diet from 0.23 ± 0.1 to 0.29 ± 0.1 liters/h/kg (p < .05). For the i.v. salt study, the disposition of single p.o. and single i.v. doses of quinidine was determined on two occasions in eight subjects: once during a low-salt diet (10 mEq/day) and once during the same diet, supplemented by 400 mEq/day NaCl i.v. for 8 days. In contrast to our findings after p.o. salt loading, i.v. salt loading did not alter the pharmacokinetics of p.o. quinidine. Taken together, these data implicate a local alteration of drug-metabolizing activity and/or drug transport in the intestinal mucosa as the major effect of dietary salt on the disposition of p.o. quinidine and further suggest that β-adrenergic activation by a low-salt diet is one component of a signaling pathway whereby intestinal drug disposition is suppressed, resulting in increased oral bioavailability.
Footnotes
-
Send reprint requests to: Dan M. Roden, M.D., Division of Clinical Pharmacology, 532 Medical Research Building-I, Vanderbilt University School of Medicine, Nashville, TN 37232. E-mail:dan.roden{at}mcmail.vanderbilt.edu
-
↵1 This work was supported in part by U.S. Public Health Service Grants GM31304, GM07569, and RR095. Dr. Fromm was supported by the Deutsche Forschungsgemeinschaft (Fr 1298/1-1, Bonn, Germany). Dr. Roden is the holder of the William Stokes Chair in Experimental Therapeutics, a gift of Daiichi Pharmaceutical.
-
↵2 These authors contributed equally to the study.
- Abbreviations:
- AUC
- area under the time-concentration curve
- AUCi.v.
- area under the plasma concentration-time curve after i.v. administration
- AUCp.o.
- area under the plasma concentration-time curve after p.o. administration
- CL
- clearance
- CLO
- apparent oral clearance
- CLS
- systemic clearance
- Cmax
- maximum quinidine concentration
- CYP
- cytochrome P-450
- t1/2
- terminal elimination half-life
- Tmax
- time to reach maximum concentration
- F
- bioavailability
- VC
- volume of distribution
- Received July 24, 1998.
- Accepted March 1, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|